Volume 101, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



The albumin–bilirubin (ALBI) score was originally established to stratify prognosis in patients with cirrhosis. The diagnostic accuracy of ALBI score in liver fibrosis staging in patients with chronic hepatitis B remains to be investigated. The present retrospective study, therefore, aimed to evaluate the ability of this score to stage liver fibrosis in these patients. Briefly, consecutive patients with hepatitis B virus (HBV) infection who underwent liver biopsy examinations in Kagawa University Hospital were enrolled. Liver fibrosis stage was assessed using a modified Meta-Analysis of Histological Data in Viral Hepatitis score. Albumin–bilirubin scores were calculated according to the following equation: (log total bilirubin [T-Bil] × 0.66) + (albumin [Alb] × −0.085). A total of 91 patients were enrolled in this study. Albumin–bilirubin score was able to differentiate stage 4 from stage 3 fibrosis ( < 0.05). When an ALBI score of −2.190 was adopted as the cutoff value for differentiating stage 4 from stages 1–3, the sensitivity, specificity, and positive likelihood ratio were 85.7%, 74.0%, and 3.300, respectively. Kaplan–Meier analysis showed that baseline ALBI scores < −2.190 correlated with better hepatocellular carcinoma (HCC)–free survival ( < 0.05). In conclusion, ALBI score can be used for liver fibrosis staging in Japanese chronic hepatitis B patients and can help distinguish cirrhotic from non-cirrhotic status. Furthermore, ALBI score was useful as a prognosis biomarker in our patients, with smaller ALBI scores predicting better HCC-free survival. Because calculating ALBI score is easy using serum T-Bil and Alb alone, ALBI score will help clinicians with decision-making in management of HBV-infected patients.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. WHO, 2018. Fact Sheet, Hepatitis B. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed January 7, 2019. [Google Scholar]
  2. Sarin SK, 2016. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10: 198. [Google Scholar]
  3. Fattovich G, , 2003. Natural history and prognosis of hepatitis B. Semin Liver Dis 23: 4758. [Google Scholar]
  4. Poh Z, Goh BB, Chang PE, Tan CK, , 2015. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients. Eur J Gastroenterol Hepatol 27: 638643. [Google Scholar]
  5. Yapali S, Talaat N, Lok AS, , 2014. Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol 12: 1626. [Google Scholar]
  6. Allain JP, Opare-Sem O, , 2016. Screening and diagnosis of HBV in low-income and middle-income countries. Nat Rev Gastroenterol Hepatol 13: 643653. [Google Scholar]
  7. Ichikawa Y, 2017. Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Hepatol Res 47: 226233. [Google Scholar]
  8. Jekarl DW, Choi H, Lee S, Kwon JH, Lee SW, Yu H, Kim M, Kim Y, Sung PS, Yoon SK, , 2018. Diagnosis of liver fibrosis with Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP) among chronic hepatitis B patients. Ann Lab Med 38: 348354. [Google Scholar]
  9. Johnson PJ, 2015. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33: 550558. [Google Scholar]
  10. World Medical Association, 2013. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310: 21912194. [Google Scholar]
  11. Vellinga A, Cormican M, Hanahoe B, Bennett K, Murphy AW, , 2011. Opt-out as an acceptable method of obtaining consent in medical research: a short report. BMC Med Res Methodol 11: 40. [Google Scholar]
  12. Montoy JC, Dow WH, Kaplan BC, , 2016. Patient choice in opt-in, active choice, and opt-out HIV screening: randomized clinical trial. BMJ 532: h6895. [Google Scholar]
  13. The French METAVIR Cooperative Study Group, 1994. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20: 1520. [Google Scholar]
  14. Bedossa P, Poynard T, , 1996. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: 289293. [Google Scholar]
  15. Chen RC, Cai YJ, Wu JM, Wang XD, Song M, Wang YQ, Zheng MH, Chen YP, Lin Z, Shi KQ, , 2017. Usefulness of albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis. J Viral Hepat 24: 238245. [Google Scholar]
  16. Li C, Zhang XY, Peng W, Wen TF, Yan LN, Li B, Yang JY, Wang WT, Xu MQ, , 2018. Postoperative albumin-bilirubin grade change predicts the prognosis of patients with hepatitis B-related hepatocellular carcinoma within the milan criteria. World J Surg 42: 18411847. [Google Scholar]
  17. Chen B, Lin S, , 2017. Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Medicine (Baltimore) 96: e7142. [Google Scholar]
  18. Cai XR, 2018. Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy. J Cancer 9: 23802388. [Google Scholar]
  19. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M, , 1992. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 103: 16301635. [Google Scholar]
  20. Chan HL, Chim AM, Lau JT, Hui AY, Wong VW, Sung JJ, , 2006. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am J Gastroenterol 101: 15161523. [Google Scholar]
  21. Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A, , 2011. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther 34: 12021216. [Google Scholar]
  22. Toshima T, 2015. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J Gastroenterol 50: 7684. [Google Scholar]
  23. Fujita K, 2019. Albumin-bilirubin score indicates liver fibrosis staging and prognosis in chronic hepatitis C patients. Hepatol Res. [Google Scholar]
  24. Fujita K, 2018. Fibrosis staging using direct serum biomarkers is influenced by hepatitis activity grading in hepatitis C virus infection. J Clin Med 7: E267. [Google Scholar]
  25. Huo TI, Wu JC, Lai CR, Lu CL, Sheng WY, Lee SD, , 1996. Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection. J Hepatol 25: 439444. [Google Scholar]
  26. Oikonomou T, Goulis I, Doumtsis P, Tzoumari T, Akriviadis E, Cholongitas E, , 2018. ALBI and PALBI grades are associated with the outcome of patients with stable decompensated cirrhosis. Ann Hepatol 18: 126136. [Google Scholar]
  27. Luo HM, Zhao SZ, Li C, Chen LP, , 2018. Preoperative platelet-albumin-bilirubin grades predict the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after liver resection: a retrospective study. Medicine (Baltimore) 97: e0226. [Google Scholar]
  28. Wong VW, Sung JJ, , 2011. Application of transient elastography in chronic hepatitis B. Aliment Pharmacol Ther 34: 817818; author reply 818–819. [Google Scholar]
  29. Venkatesh SK, Wang G, Lim SG, Wee A, , 2014. Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. Eur Radiol 24: 7078. [Google Scholar]

Data & Media loading...

Supplemental tables

  • Received : 11 Feb 2019
  • Accepted : 25 Mar 2019
  • Published online : 20 May 2019

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error